Pluristem Appoints Dr. Edwin Horwitz to Scientific Advisory Board
News May 26, 2006
Pluristem Life Systems, Inc. has announced that Edwin M Horwitz, M.D., PhD. has joined the Company's Scientific Advisory Board.
Professor Horwitz is a pioneer and world-renowned leader in the clinical use of stem cells. He is recognized for his work on the transplantation of pre-selected hematopoietic stem cells and for his contribution to the field of mesenchymal cell therapy.
Professor Horwitz is the recipient and principal investigator of multiple NIH and other grants in the field of mesenchymal cell therapy.
Nature Medicine published his first work, addressing use of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta, in 1999.
Professor Horwitz is the chairman of the Mesenchymal Stem Cell scientific committee of the International Society of Cellular Therapy (ISCT) and co-chair of the committee on gene marking of the Center for International Blood and Marrow Transplant Research.
"We are honored by Prof. Horwitz's decision to join our company and to help us in the development of Pluristem as a market leader in cell therapy products," said Zami Aberman, CEO of Pluristem.
"I'm sure that his expertise and experience will contribute enormously to our product development and clinical programs."
Prof Horwitz stated, "Pluristem is working hard on developing technologies that aims to solve the global shortfall in matched tissue for transplantation."
"This is a major unmet medical need and I look forward to being able to contribute to Pluristem's exciting R&D program."
The spatial and temporal dynamics of proteins or organelles plays a crucial role in controlling various cellular processes and in development of diseases. However, acute control of activity at distinct locations within a cell cannot be achieved. A new chemo-optogenetic method enables tunable, reversible, and rapid control of activity at multiple subcellular compartments within a living cell.